Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Prasugrel meets ACS endpoint

Eli Lilly (LLY) and Daiichi Sankyo (Tokyo:4568; Osaka:4568) said prasugrel met the

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE